Developer docs
API playgroundTry for free, no card

Search company profiles

Precirix

Full company profile

uuid00026b3

Namestring
Precirix
Legal namestring
Precirix NV
Websiteurl
precirix.com
Company typeenum
Private
Founded yearint
2014
Descriptiontext

Precirix is a privately-held clinical-stage biopharmaceutical company headquartered in Brussels, Belgium, founded in 2014 as a Vrije Universiteit Brussel (VUB) spin-off (originally named Camel-IDS, rebranded in September 2020). The company designs and develops precision radiopharmaceuticals for cancer treatment using a proprietary platform built on camelid single-domain antibodies (sdAbs) labeled with therapeutic and diagnostic radiometals. Its lead asset CAM-H2 is an sdAb targeting HER2, labeled with Iodine-131, currently in a Phase I/II study (NCT04467515) for HER2-positive metastatic breast and gastric cancer, including brain metastases where limited options exist. The pipeline has expanded to include CAM-FAP-Ac-225 (targeted alpha therapy against fibroblast activation protein, FDA IND accepted July 2025), CAM-FAP-Ga-68 (companion diagnostic imaging agent), CAM-HER2-Pb-212 (Lead-212 alpha therapy via partnership with Orchestra Life Sciences), and CAM-FR (folate receptor alpha, preclinical for ovarian cancer).

The sdAb platform is designed to combine the high target specificity of monoclonal antibodies with the fast tumor penetration and rapid blood clearance of peptides, enabling targeted radionuclide therapy with long tumor retention times while sparing healthy tissue. The platform is multi-isotope (I-131, Ac-225, Pb-212, Ga-68) and theranostic-capable, allowing the same molecule to be used for patient imaging and treatment selection followed by therapeutic dosing. Precirix is pre-revenue and its stated revenue model is one-time licensing or future product sales following regulatory approval; the company currently monetizes its research through scientific publishing, conference presentations, and an Academic Access Program for CAM-FAP-Ga-68, while clinical manufacturing is outsourced to CDMOs (3P Biopharmaceuticals, Evergreen Theragnostics, IFE) and isotope supply is secured via Eckert & Ziegler and Orchestra Life Sciences partnerships. CAM-H2 is explicitly available for partnering or out-licensing, and the company has signaled openness to strategic transactions for the platform or programs.

Short descriptiontext

Precirix is a clinical-stage Brussels-based biopharmaceutical company developing precision radiopharmaceuticals that use camelid single-domain antibodies labeled with radiometals to treat HER2-positive and FAP-expressing solid tumors, with CAM-H2 in Phase I/II and CAM-FAP-Ac-225 IND-approved.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersBrussels, Belgium
HQ citystring
Brussels
HQ countrystring
Belgium
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
precision radiopharmaceuticals, targeted radionuclide therapy, single-domain antibodies, targeted alpha therapy, oncology drug development
Industry3 codes
PRIMARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAAAA
Monoclonal Antibody Therapeutics (mAbs)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Precision Radiopharmaceuticals / Targeted Radionuclide Therapy
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Radiopharmaceutical Development
TypeOne Time License
Description

Pre-revenue clinical stage company developing precision radiopharmaceuticals for cancer treatment. Revenue will be generated through product sales upon regulatory approval.

precirix.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Precirix develops precision radiopharmaceuticals that combine camelid single-domain antibodies (sdAbs) with therapeutic and diagnostic radioisotopes to selectively target cancer cells. Its lead candidates include CAM-H2 (HER2-targeting, Iodine-131, in Phase I/II), CAM-FAP-Ac-225 (FAP-targeting alpha therapy, FDA IND accepted July 2025), CAM-FAP-Ga-68 diagnostic imaging agent, CAM-HER2-Pb-212, and CAM-FR. The company generates value primarily through out-licensing and partnering of its assets rather than direct commercialization.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Phase I study completed demonstrating safety and specific targeting of cancer cells
+2 more records
Product overview1 text field

Precirix is a clinical-stage biopharmaceutical company developing precision radiopharmaceuticals using camelid single-domain antibodies (sdAbs) labeled with radiometals. The company's portfolio consists of its proprietary CAM-TRT Platform enabling development of sdAb-based radiopharmaceuticals, with lead products including CAM-H2 (HER2-targeting with Iodine-131, in Phase I/II), CAM-FAP-Ac-225 (FAP-targeting with Actinium-225, IND approved July 2025 for Phase 1), CAM-FAP-Ga-68 (diagnostic imaging agent), CAM-HER2-Pb-212 (Lead-212 therapeutic with Orchestra Life Sciences), and CAM-FR (folate receptor targeting for ovarian cancer in preclinical stage). The platform enables both therapeutic and diagnostic (theranostic) applications.

Product and service4 records
1CAM-H2
CategoryCore therapeutic product (radiopharmaceutical drug candidate)
Description

HER2-targeting camelid single-domain antibody (sdAb) radiolabeled with Iodine-131, designed to effectively irradiate HER2-positive metastatic cancers including brain metastases while sparing healthy tissue. Currently in Phase I/II clinical trial. Available for partnering or out-licensing.

2CAM-FAP-Ac-225
CategoryCore therapeutic product (radiopharmaceutical drug candidate)
Description

Single-domain antibody construct targeting Fibroblast Activation Protein alpha (FAP) labeled with Actinium-225 for targeted alpha therapy of FAP-expressing solid tumors. Lead clinical program; potential first-in-class alpha-emitting targeted radiotherapy against the pan-tumor target FAP.

3CAM-FAP-Ga-68
CategoryDiagnostic radiopharmaceutical product
Description

Gallium-68 labeled imaging agent for PET imaging of FAP-expressing solid tumors. Offered to academic researchers through the CAM-FAP Academic Access Program for investigator-initiated imaging studies.

4CAM-HER2-Pb-212
Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-08-04
Description

Research collaboration on radio-fluorination for sdAbs and immune modulation studies. VUB is the academic institution where Precirix originated as a spin-off in 2014.

Strategic tierStrategicTypeTechnology or IntegrationAnnounced on2024-07-03
Description

Strategic partnership for access to Lead-212 (Pb-212) radioisotope through Orchestra's TAG1 generator for targeted alpha therapy development.

3Eckert & Ziegler Eurotope
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2022-09-12
Description

Collaboration for development of automated production process for 68Ga-based diagnostic compounds using Eckert & Ziegler's synthesis equipment.

precirix.com
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2022-07-26
Description

Agreement for priority supply of Actinium-225 radioisotope for clinical trials. German company specializing in isotope-related components for nuclear medicine.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-09-13
Description

Clinical trial manufacturing agreement for supply of radiopharmaceuticals in Europe. Norwegian manufacturer of radiopharmaceutical products.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-08-17
Description

Alliance for clinical manufacturing of single domain antibodies. CDMO based in Spain specializing in process development and GMP manufacturing of biological products.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-04-28
Description

Manufacturing partnership for CAM-H2 production at Evergreen's state-of-the-art GMP facility in Springfield, New Jersey. Supports North American clinical trial supply.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Australian commercial-stage radiopharma company developing HER2-targeted imaging (TLX591) and a broader pipeline of targeted radiopharmaceuticals. Most directly comparable to Precirix given overlapping HER2 radiopharma programs and parallel therapeutic-plus-diagnostic strategies.

TypeDirect peer
Description

Radioligand therapy company developing PNT2002 (PSMA-Lu-177) and PNT2003 plus actinium-based alpha programs. Acquired by Eli Lilly for $1.4B in 2023. Closely comparable clinical-stage radiopharma with parallel alpha/beta emitter strategy.

TypeDirect peer
Description

Canadian targeted alpha therapy company developing Ac-225-based radiopharmaceuticals across multiple targets. Acquired by AstraZeneca for $2.4B in 2024. Highly comparable as clinical-stage alpha-emitter specialist.

TypeDirect peer
Description

US radiopharmaceutical company developing actinium-225-based targeted radiotherapies for solid tumors. Acquired by Bristol Myers Squibb for $4.1B in 2024. Direct peer given parallel alpha-emitter therapeutic focus.

TypeDirect peer
Description

German radiopharmaceutical company developing targeted radionuclide therapies (Lu-177 and Ac-225 based) with own isotope production capabilities. Comparable clinical-stage radioligand therapy developer with European footprint.

TypeBroad incumbent
Description

Owner of Lutathera (Lu-177) and Pluvicto (Lu-177 PSMA-617), the dominant approved radioligand therapy franchise. Broad incumbent setting competitive benchmarks for all clinical-stage radiopharma developers including Precirix.

TypeBroad incumbent
Description

Acquired Algeta ASA for $2.9B in 2014, gaining Xofigo (Ra-223) and alpha-emitter expertise. Major incumbent in radiopharmaceuticals with established commercial and manufacturing infrastructure.

TypeBroad incumbent
Description

US radiopharmaceutical company with approved products (Definity, Xenon-133) and pipeline including PSMA-targeted and other radioligand therapies. Broad incumbent serving as M&A consolidator in the radiopharma space.

TypeDirect peer
Description

US clinical-stage company developing alpha-emitting radiotherapies (Ac-225, I-131) for hematologic and solid tumors. Direct peer with similar early-clinical-stage profile and alpha-emitter focus.

TypeDirect peer
Description

Berlin-based clinical-stage radiopharma company developing sdAb-based radiopharmaceuticals for solid tumors. Highly comparable to Precirix given parallel use of single-domain antibody scaffolds and targeted radionuclide therapy approach.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Precirix

Precision Radiopharmaceuticals / Targeted Radionuclide Therapyprecirix.com

Precirix is a clinical-stage Brussels-based biopharmaceutical company developing precision radiopharmaceuticals that use camelid single-domain antibodies labeled with radiometals to treat HER2-positive and FAP-expressing solid tumors, with CAM-H2 in Phase I/II and CAM-FAP-Ac-225 IND-approved.

What Precirix does

Precirix is a privately-held clinical-stage biopharmaceutical company headquartered in Brussels, Belgium, founded in 2014 as a Vrije Universiteit Brussel (VUB) spin-off (originally named Camel-IDS, rebranded in September 2020). The company designs and develops precision radiopharmaceuticals for cancer treatment using a proprietary platform built on camelid single-domain antibodies (sdAbs) labeled with therapeutic and diagnostic radiometals. Its lead asset CAM-H2 is an sdAb targeting HER2, labeled with Iodine-131, currently in a Phase I/II study (NCT04467515) for HER2-positive metastatic breast and gastric cancer, including brain metastases where limited options exist. The pipeline has expanded to include CAM-FAP-Ac-225 (targeted alpha therapy against fibroblast activation protein, FDA IND accepted July 2025), CAM-FAP-Ga-68 (companion diagnostic imaging agent), CAM-HER2-Pb-212 (Lead-212 alpha therapy via partnership with Orchestra Life Sciences), and CAM-FR (folate receptor alpha, preclinical for ovarian cancer).

The sdAb platform is designed to combine the high target specificity of monoclonal antibodies with the fast tumor penetration and rapid blood clearance of peptides, enabling targeted radionuclide therapy with long tumor retention times while sparing healthy tissue. The platform is multi-isotope (I-131, Ac-225, Pb-212, Ga-68) and theranostic-capable, allowing the same molecule to be used for patient imaging and treatment selection followed by therapeutic dosing. Precirix is pre-revenue and its stated revenue model is one-time licensing or future product sales following regulatory approval; the company currently monetizes its research through scientific publishing, conference presentations, and an Academic Access Program for CAM-FAP-Ga-68, while clinical manufacturing is outsourced to CDMOs (3P Biopharmaceuticals, Evergreen Theragnostics, IFE) and isotope supply is secured via Eckert & Ziegler and Orchestra Life Sciences partnerships. CAM-H2 is explicitly available for partnering or out-licensing, and the company has signaled openness to strategic transactions for the platform or programs.

Precirix firmographics

Firmographics
Name
Precirix
Legal name
Precirix NV
Website
https://precirix.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
1–10 employees
Short description
Precirix is a clinical-stage Brussels-based biopharmaceutical company developing precision radiopharmaceuticals that use camelid single-domain antibodies labeled with radiometals to treat HER2-positive and FAP-expressing solid tumors, with CAM-H2 in Phase I/II and CAM-FAP-Ac-225 IND-approved.
Ownership category
akta.pro rank

Precirix industry classification

Industry
Product category
Precision Radiopharmaceuticals / Targeted Radionuclide Therapy
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAAAA
Monoclonal Antibody Therapeutics (mAbs)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

  • Precision radiopharmaceuticals
  • Targeted radionuclide therapy
  • Single-domain antibodies
  • Targeted alpha therapy
  • Oncology drug development

Where Precirix is headquartered

Location

Headquarters

HQ city
Brussels
HQ country
Belgium
HQ region
Europe

Offices1 record

Markets served

Precirix business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Radiopharmaceutical Development: Pre-revenue clinical stage company developing precision radiopharmaceuticals for cancer treatment. Revenue will be generated through product sales upon regulatory approval.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Precirix product offering

Product offering

Core offering

Precirix develops precision radiopharmaceuticals that combine camelid single-domain antibodies (sdAbs) with therapeutic and diagnostic radioisotopes to selectively target cancer cells. Its lead candidates include CAM-H2 (HER2-targeting, Iodine-131, in Phase I/II), CAM-FAP-Ac-225 (FAP-targeting alpha therapy, FDA IND accepted July 2025), CAM-FAP-Ga-68 diagnostic imaging agent, CAM-HER2-Pb-212, and CAM-FR. The company generates value primarily through out-licensing and partnering of its assets rather than direct commercialization.

Product overview

Precirix is a clinical-stage biopharmaceutical company developing precision radiopharmaceuticals using camelid single-domain antibodies (sdAbs) labeled with radiometals. The company's portfolio consists of its proprietary CAM-TRT Platform enabling development of sdAb-based radiopharmaceuticals, with lead products including CAM-H2 (HER2-targeting with Iodine-131, in Phase I/II), CAM-FAP-Ac-225 (FAP-targeting with Actinium-225, IND approved July 2025 for Phase 1), CAM-FAP-Ga-68 (diagnostic imaging agent), CAM-HER2-Pb-212 (Lead-212 therapeutic with Orchestra Life Sciences), and CAM-FR (folate receptor targeting for ovarian cancer in preclinical stage). The platform enables both therapeutic and diagnostic (theranostic) applications.

Differentiator

Problem solved

Functional benefit

Products and services

  • CAM-H2 HER2-targeting camelid single-domain antibody (sdAb) radiolabeled with Iodine-131, designed to effectively irradiate HER2-positive metastatic cancers including brain metastases while sparing healthy tissue. Currently in Phase I/II clinical trial. Available for partnering or out-licensing.
  • CAM-FAP-Ac-225 Single-domain antibody construct targeting Fibroblast Activation Protein alpha (FAP) labeled with Actinium-225 for targeted alpha therapy of FAP-expressing solid tumors. Lead clinical program; potential first-in-class alpha-emitting targeted radiotherapy against the pan-tumor target FAP.
  • CAM-FAP-Ga-68 Gallium-68 labeled imaging agent for PET imaging of FAP-expressing solid tumors. Offered to academic researchers through the CAM-FAP Academic Access Program for investigator-initiated imaging studies.
  • CAM-HER2-Pb-212

Quantifiable outcome

  • Phase I study completed demonstrating safety and specific targeting of cancer cells
  • +2 more outcomes

Companies that use Precirix

Customer profile

Segments3 records

Ideal customer profiles3 records

Precirix technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Precirix partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core and strategic.

  • Vrije Universiteit Brussel (VUB)coreStrategic or Co-development Partner · 4 August 2025Research collaboration on radio-fluorination for sdAbs and immune modulation studies. VUB is the academic institution where Precirix originated as a spin-off in 2014.
  • Orchestra Life SciencesstrategicTechnology or Integration · 3 July 2024Strategic partnership for access to Lead-212 (Pb-212) radioisotope through Orchestra's TAG1 generator for targeted alpha therapy development.
  • Eckert & Ziegler EurotopecoreTechnology or Integration · 12 September 2022Collaboration for development of automated production process for 68Ga-based diagnostic compounds using Eckert & Ziegler's synthesis equipment.
  • Eckert & ZieglercoreTechnology or Integration · 26 July 2022Agreement for priority supply of Actinium-225 radioisotope for clinical trials. German company specializing in isotope-related components for nuclear medicine.
  • IFE (Institute for Energy Technology)coreStrategic or Co-development Partner · 13 September 2021Clinical trial manufacturing agreement for supply of radiopharmaceuticals in Europe. Norwegian manufacturer of radiopharmaceutical products.
  • 3P BiopharmaceuticalscoreStrategic or Co-development Partner · 17 August 2021Alliance for clinical manufacturing of single domain antibodies. CDMO based in Spain specializing in process development and GMP manufacturing of biological products.
  • Evergreen TheragnosticscoreStrategic or Co-development Partner · 28 April 2021Manufacturing partnership for CAM-H2 production at Evergreen's state-of-the-art GMP facility in Springfield, New Jersey. Supports North American clinical trial supply.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

Precirix competitors and assessment

Company assessment

Direct peers

  • Telix Pharmaceuticals: Australian commercial-stage radiopharma company developing HER2-targeted imaging (TLX591) and a broader pipeline of targeted radiopharmaceuticals. Most directly comparable to Precirix given overlapping HER2 radiopharma programs and parallel therapeutic-plus-diagnostic strategies.
  • POINT Biopharma: Radioligand therapy company developing PNT2002 (PSMA-Lu-177) and PNT2003 plus actinium-based alpha programs. Acquired by Eli Lilly for $1.4B in 2023. Closely comparable clinical-stage radiopharma with parallel alpha/beta emitter strategy.
  • Fusion Pharmaceuticals: Canadian targeted alpha therapy company developing Ac-225-based radiopharmaceuticals across multiple targets. Acquired by AstraZeneca for $2.4B in 2024. Highly comparable as clinical-stage alpha-emitter specialist.
  • RayzeBio: US radiopharmaceutical company developing actinium-225-based targeted radiotherapies for solid tumors. Acquired by Bristol Myers Squibb for $4.1B in 2024. Direct peer given parallel alpha-emitter therapeutic focus.
  • ITM Isotope Technologies Munich: German radiopharmaceutical company developing targeted radionuclide therapies (Lu-177 and Ac-225 based) with own isotope production capabilities. Comparable clinical-stage radioligand therapy developer with European footprint.
  • Actinium Pharmaceuticals: US clinical-stage company developing alpha-emitting radiotherapies (Ac-225, I-131) for hematologic and solid tumors. Direct peer with similar early-clinical-stage profile and alpha-emitter focus.
  • Ariceum Therapeutics: Berlin-based clinical-stage radiopharma company developing sdAb-based radiopharmaceuticals for solid tumors. Highly comparable to Precirix given parallel use of single-domain antibody scaffolds and targeted radionuclide therapy approach.

Broad incumbents

  • Novartis (Advanced Accelerator Applications): Owner of Lutathera (Lu-177) and Pluvicto (Lu-177 PSMA-617), the dominant approved radioligand therapy franchise. Broad incumbent setting competitive benchmarks for all clinical-stage radiopharma developers including Precirix.
  • Bayer (Pharmaceuticals): Acquired Algeta ASA for $2.9B in 2014, gaining Xofigo (Ra-223) and alpha-emitter expertise. Major incumbent in radiopharmaceuticals with established commercial and manufacturing infrastructure.
  • Lantheus Holdings: US radiopharmaceutical company with approved products (Definity, Xenon-133) and pipeline including PSMA-targeted and other radioligand therapies. Broad incumbent serving as M&A consolidator in the radiopharma space.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Precirix social profiles

Digital presence

Precirix financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Precirix leadership team

Management profile

Number of profiles

Profiles13 records

Precirix funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Precirix M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Precirix

What does Precirix do?

Precirix develops precision radiopharmaceuticals that combine camelid single-domain antibodies (sdAbs) with therapeutic and diagnostic radioisotopes to selectively target cancer cells. Its lead candidates include CAM-H2 (HER2-targeting, Iodine-131, in Phase I/II), CAM-FAP-Ac-225 (FAP-targeting alpha therapy, FDA IND accepted July 2025), CAM-FAP-Ga-68 diagnostic imaging agent, CAM-HER2-Pb-212, and CAM-FR. The company generates value primarily through out-licensing and partnering of its assets rather than direct commercialization.

Is Precirix a public or private company?

Precirix is a private company. It is classified as venture growth investor backed and is currently operating.

When was Precirix founded?

Precirix was founded in 2014. It employs 1 to 10 people.

Where is Precirix based?

Precirix is headquartered in Brussels, Belgium, in the Europe region.

How does Precirix make money?

One revenue line is on record: radiopharmaceutical Development.

Who are Precirix's main competitors?

Direct peers on record are Telix Pharmaceuticals, POINT Biopharma, Fusion Pharmaceuticals, RayzeBio, ITM Isotope Technologies Munich, Actinium Pharmaceuticals and Ariceum Therapeutics. Broad incumbents are Novartis (Advanced Accelerator Applications), Bayer (Pharmaceuticals) and Lantheus Holdings.

Does Precirix have an API?

No public API is recorded for Precirix.

What industry is Precirix in?

Precirix's product category is Precision Radiopharmaceuticals / Targeted Radionuclide Therapy. Its primary akta.pro industry code is HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering), with a secondary code of HLAAAAAA, Monoclonal Antibody Therapeutics (mAbs). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FinSMEsPrecirix Raises €80M in Series B FundingPrecirix NV raised €80M in Series B funding led by INKEF Capital, Jeito Capital, and Forbion. The funds will advance its lead product candidate CAM-H2 in a Phase I/II study and expand operations. The company plans to bring additional radiopharmaceuticals to the clinic.PharmiWeb.comPrecirix raises EUR 80m in Series B to advance its pipeline of precision radiopharmaceuticalsPrecirix NV, a clinical-stage biotechnology company developing precision radiopharmaceuticals in oncology, closed a EUR 80 million Series B round led by INKEF Capital, Jeito Capital and Forbion as co-leads on 16 March 2022. The company's lead candidate, CAM-H2, is in a Phase I/II study for HER2-positive metastatic breast and gastric cancer, with patients now enrolled in the second dose-escalation cohort. Proceeds will fund pipeline development, platform strengthening and additional radiopharmaceuticals.Silicon CanalsBelgian biotech company Precirix secures €80M from Amsterdam-based INKEF Capital, othersBrussels-based biotech company Precirix raised €80 million in a Series B funding round led by INKEF Capital, Jeito Capital, and Forbion. The funds will be used to advance its lead product candidate CAM-H2 through Phase I/II clinical trials for cancer treatment and expand its radiopharmaceutical pipeline.GlobeNewswireJeito Capital co-leads EUR 80 million Series B financing in European oncology company, PrecirixJeito Capital co-led an €80 million Series B financing in Precirix, a clinical-stage oncology biotech, alongside INKEF Capital and Forbion. The funds will advance its lead product candidate CAM-H2 in a Phase I/II study and expand its pipeline. Jeito's Managing Partner Sabine Dandiguian will join Precirix's board.PR NewswirePrecirix raises EUR 80m in Series B to advance its pipeline of precision radiopharmaceuticalsClinical-stage biotechnology company Precirix NV closed a EUR 80 million Series B round on March 16, 2022, led by INKEF Capital, Jeito Capital and Forbion as co-leads, with existing shareholders participating. The company's lead candidate, CAM-H2, is in a Phase I/II study for HER2-positive metastatic breast and gastric cancer, including brain metastases. Proceeds will fund pipeline development, platform strengthening and additional clinical candidates.GlobeNewswireJeito Capital co-leads EUR 80 million Series B financing in European oncology company, PrecirixJeito Capital co-led an €80 million Series B financing round for Precirix, a clinical-stage biotechnology company developing precision radiopharmaceuticals for oncology. The investment was made alongside INKEF Capital and Forbion to fund the advancement of Precirix's pipeline, including its lead candidate CAM-H2 currently in Phase I/II trials. This funding supports Precirix's efforts to expand its technology platform and accelerate the development of next-generation therapies.PrecirixPrecirix raises EUR 80m in Series BPrecirix raised EUR 80 million in a Series B funding round led by new investors Inkef, Jeito, and Forbion, with participation from existing shareholders. The capital will be used to advance its lead candidate CAM-H2 through ongoing Phase I/II clinical trials for HER2-positive metastatic breast and gastric cancer and to expand its radiopharmaceutical pipeline. New partners from the investing firms will join Precirix’s Board of Directors to support this growth trajectory.PR NewswirePrecirix partners with Evergreen to expand North American clinical trial supplyPrecirix NV, a clinical-stage biotechnology company based in Brussels, has partnered with Evergreen Theragnostics, Inc. to manufacture its lead radiopharmaceutical candidate CAM-H2 in the United States. Evergreen will produce CAM-H2, an I-131 based therapy for HER2-positive metastatic breast and gastric cancer currently in Phase I/II trials, at its new GMP facility in Springfield, New Jersey. The agreement establishes Precirix's North American manufacturing footprint to ensure reliable clinical trial supply.